OMRON Healthcare, Inc., the world’s leading manufacturer and distributor of personal heart health products, has successfully concluded a three-month study demonstrating how remotely monitored vital signs can facilitate early medical intervention in patients with heart failure.
Conducted in collaboration with Kyoto Prefectural University of Medicine, with support from Japan’s Ministry of Economy, Trade and Industry (METI), the study examined how real-time sharing of patient data, including blood pressure, body weight, and electrocardiogram (ECG) readings, can detect early signs of heart failure.
During the study, patients recorded daily measurements at home using OMRON’s smart health devices and the OMRON connect mobile app. This data was automatically shared with certified cardiovascular nurses and heart failure care experts who monitored the changes remotely. In cases where potential indicators of heart failure were observed, patients were contacted directly and referred for clinical evaluation.
Also Read: OMRON Healthcare Names Alice Koehler as North America Managing Director
Early detection is crucial for patients with heart failure, and this study saw warning signs detected in some 52% of participants (7 out of 21patients), thereby enabling early intervention and treatment. By preempting the development of potentially severe or life-threatening symptoms, this approach can not only ease the burden on healthcare resources, but also bring clear benefits in reducing medical costs for patients.
Ultimately, over 90% of participants continued their daily health measurements for three months, with 86% reporting high satisfaction with the integration of home-based data into their personal health journey.
Click here to join our WhatsApp channel here
Such a system represents a significant advance on the standard approach in Japan, which sees patients self-report their symptoms via handwritten journals, which are only reviewed retrospectively during outpatient visits. With such appointments typically taking place every two to three months, there is a risk that conditions may worsen between visits, negating the opportunity for timely intervention.
